Status:
UNKNOWN
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
Lead Sponsor:
Auxilio Mutuo Cancer Center
Conditions:
Gastric Adenocarcinoma
Adenocarcinoma of the Gastroesophageal Junction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Guanabana, known also as Graviola or Annona muricata is a tropical fruit which has been commonly used as complimentary/alternative medicine in Latin American countries. The main compounds in Graviola ...
Detailed Description
Patients with relapsed/refractory gastric adenocarcinoma, adenocarcinoma of gastroesophageal junction, hepatocellular carcinoma, colorectal adenocarcinoma will be eligible. Colorectal adenocarcinomas ...
Eligibility Criteria
Inclusion
- Understand and voluntarily sign an informed consent form.
- Age \> 18 years at the time of signing the informed consent form.
- Willing and able to adhere to the study visit schedule and other protocol requirements.
- Must have measurable or evaluable disease.
- All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 2 weeks prior to treatment in this study.
- Performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale at study entry.
Exclusion
- Patients actively taking guanabana or guanabana tea daily or who have used it at some point after their diagnosis of cancer.
- Patients with Parkinson's disease.
- Serum Total Bilirubin ≥ 3.0 mg/dL
- Serum Creatinine level ≥ 3.0 mg/dL
- Central Nervous System (CNS) involvement.
- Known human immunodeficiency virus (HIV) infection; Known active hepatitis B or hepatitis C infection.
- Females who are pregnant (positive urine test) or breast-feeding females.
- Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator, would compromise the subject's ability to safely complete the study.
Key Trial Info
Start Date :
November 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04773769
Start Date
November 7 2018
End Date
November 1 2023
Last Update
February 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auxilio Mutuo Cancer Center
San Juan, Puerto Rico, 00918